Contact Us
Drug Search Results
More Filters [+]

Fotemustine

Alternative Names: fotemustine
Latest Update: 2024-03-27
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Alkylating Agent

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Czech | France | Greece | Hungary | India | Italy | Latvia | Luxembourg | New Zealand | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Thailand | Turkey | Ukraine

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Fotemustine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Uveal Melanoma|Melanoma|Brain Cancer

Phase 2: Multiple Myeloma|Glioma|Glioblastoma|Melanoma|Brain Cancer|Non-Small-Cell Lung Cancer|Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
FOTE ADJ

P3

Completed

Unknown

2020-06-12

2006-7041-83/hah

N/A

Not yet recruiting

Other

2019-05-15

14-N-0086

N/A

Not yet recruiting

Stroke|Depressive Disorder|Mental Fatigue

2018-10-01

NIBIT-M2

P3

Unknown status

Brain Cancer|Melanoma

2018-01-01

Recent News Events

Date

Type

Title

03/27/2024

PubMed

 Metabolic models predict fotemustine and the combination of eflornithine/rifamycin and adapalene/cannabidiol for the treatment of gliomas.

03/01/2024

PubMed

 Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.

01/01/2024

PubMed

 Nitrosoureas Toxicity.

11/07/2022

News Article

 10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH

04/08/2021

News Article

 Worldwide Neuroendocrine Tumor Treatment Industry to 2029 - Players Include Advanced Accelerator Applications, Novartis & Progenics Pharmaceuticals Among Others - ResearchAndMarkets.com

09/03/2020

News Article

 Small Molecule Cancer Drugs Industry Report 2020-2026 - Clinical Trials Insight on >2,500 Drugs by Phase, Company, Country, Formulation and Indication

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions